Key result
Prior oral mucositis during anthracycline-cyclophosphamide linked to ~350% higher mucositis risk during first docetaxel cycle.
Why the study?
Prior data linked oral mucositis from anthracycline-cyclophosphamide to symptoms following subsequent docetaxel-containing chemotherapy, but concomitant pertuzumab and trastuzumab may confound this risk. The study evaluated the direct relationship of oral mucositis with anthracycline-cyclophosphamide and subsequent docetaxel monotherapy.
Does the presence of oral mucositis during prior anthracycline-cyclophosphamide treatment increase the risk of oral mucositis during subsequent docetaxel monotherapy in breast cancer patients?
Cohort (n=63)
Does the presence of oral mucositis during prior anthracycline-cyclophosphamide treatment increase the risk of oral mucositis during subsequent docetaxel monotherapy in breast cancer patients?
Absolute Event Rate: 42.9% vs 9.5%
p-value: p=0.006
Patients who develop oral mucositis during anthracycline-cyclophosphamide therapy are at significantly higher risk of developing it during subsequent docetaxel monotherapy.
Prior OM may flag higher docetaxel mucositis risk; leaves open prospective validation before informing practice.
Background/Aim: We have previously reported that patients experiencing oral mucositis (OM) during anthracycline-cyclophosphamide treatment develop symptoms following subsequent docetaxel-containing chemotherapy for perioperative breast cancer therapy. However, the concomitant use of pertuzumab and trastuzumab with docetaxel has also been suggested as a significant risk factor for OM. This study aimed to further evaluate the direct relationship of OM with anthracycline-cyclophosphamide treatment and docetaxel monotherapy. Patients and Methods: Patients with breast cancer who underwent anthracycline-cyclophosphamide treatment followed by docetaxel monotherapy as perioperative therapy (n=63) were divided into control and OM-experience groups based on the absence or presence of OM development during prior anthracycline-cyclophosphamide treatment, and retrospectively evaluated. The primary endpoint was the comparison of all-grade OM incidence in the first docetaxel cycle between the two groups. The incidence of OM and dysgeusia was also assessed across all treatment cycles. Results: The incidence of all-grade OM was 42.9% in the OM-experience group and 9.5% in the control group during the first cycle (p=0.006) and 47.6% and 11.9% across all treatment cycles (p=0.004), thereby achieving the primary endpoint. In contrast, the incidence of grade ≥2 OM in both settings was higher in the OM-experience group than in the control group, although the difference was not statistically significant (14.3% vs. 2.4%, p=0.10 for both settings). Moreover, the incidence of dysgeusia did not differ between the two groups. Conclusion: Patients exhibiting OM during prior anthracycline-cyclophosphamide treatment were significantly more likely to develop symptoms during subsequent docetaxel monotherapy for perioperative breast cancer therapy.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2025) conducted a cohort in Breast cancer (n=63). Prior oral mucositis during anthracycline-cyclophosphamide treatment vs. No prior oral mucositis during anthracycline-cyclophosphamide treatment was evaluated on Incidence of all-grade oral mucositis in the first docetaxel cycle (p=0.006). Prior oral mucositis during anthracycline-cyclophosphamide treatment was associated with a higher incidence of all-grade oral mucositis during the first docetaxel cycle (42.9% vs 9.5%, p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: